Education
About Us
Working with TipRanks
Follow Us
Prothena (DE:0PT)
FRANKFURT:0PT
0PT Stock Chart & Stats
€7.45
€0.00(0.00%)
At close: 4:00 PM EST
€7.45
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.86 - €15.20
Previous CloseN/A
Volume0.00
Average Volume (3M)27.00
Market Cap
€416.16M
Enterprise Value€183.50M
Total Cash (Recent Filing)€330.84M
Total Debt (Recent Filing)€9.08M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
May 13, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding53,829,983
10 Day Avg. Volume81
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.53
Price to Sales (P/S)5.51
P/FCF Ratio-4.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.51Price Target Upside161.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intracellular And Brain Delivery CapabilityCYTOPE's ability to deliver large therapeutic molecules into the cell cytosol and across the blood-brain barrier while avoiding membrane-disrupting toxicity addresses limitations of traditional antibodies and small molecules.
Partnered Late-stage ValidationAdvancement of partnered programs with major biopharma collaborators into late-stage clinical testing provides external validation and potential material value inflection as those programs progress.
Platform DifferentiationStrategic focus on two proprietary platforms, CYTOPE and transferrin receptor-mediated delivery, could unlock novel treatment approaches that extend value beyond existing partnered programs.
Bears Say
Clinical Track Record In Parkinson's DiseasePrasinezumab's previous failure to show a statistically significant benefit in early-stage Parkinson's disease and the historical difficulty demonstrating efficacy in late-stage Parkinson's trials reduce the probability of a successful outcome.
Commercial Competition And PositioningCoramitug would enter a crowded market and is likely to be used as a later-line therapy for more severe patients, which could constrain market share and revenue potential.
Platform Applicability And IP RiskUncertainty about whether the platform can be applied to other intracellular proteinopathies and questions about the strength of the platform-specific patent estate could limit broad adoption and competitive protection if clinical validation is incomplete.
Prothena News
0PT FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was €3.86 and its highest was €15.20 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is €416.16M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is May 13, 2026 which is in 79 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Feb 19, 2026. The company reported -€0.338 earnings per share for the quarter, beating the consensus estimate of -€0.473 by €0.134.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.31.
How many shares outstanding does Prothena have?
Prothena has 53,829,983 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -€0.338 in its last earnings report, beating expectations of -€0.473. Following the earnings report the stock price went down -1.974%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in DE:0PT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.51 (161.88% Upside)
€19.51 (161.88% Upside)
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.42%
12-Months-Change
Fundamentals
Return on Equity
-67.63%
Trailing 12-Months
Asset Growth
-40.76%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
0PT Company Deck
0PT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.View all DE:0PT earnings summaries0PT Stock 12 Month Forecast
Average Price Target
€19.51
▲(161.88% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
XOMA Royalty Corporation
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Options Prices
Currently, No data available
---